Yu. V. Baihush

Yu. V. Baihush

Auto-generated profile, based on publicly available information

Yu. V. Baihush

Івано-Франківський національний медичний університет

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 October 2022 in ScienceRise: Pharmaceutical Science
Verified
Journal Article
Open access
PDF file
OSOleh Samborskyi
Oleh Samborskyi
НPНanna Panfilova
Нanna Panfilova
YBYuliia Baihush
Yuliia Baihush
LSLiusine Simonian
Liusine Simonian
IBIryna Bilyk
Iryna Bilyk
VCVitaly Chernukha
Vitaly Chernukha
The aim: to conduct an analysis of the state of functioning of pharmaceutical supply systems for the population in European countries and Ukraine based on a set of socio-economic indicators. Materials and methods. General theoretical (historical, formal, graphic, hypothetical-deductive) and applied (organizational-economic, mathematical-statistical) research methods were used. The object of research was data that was freely available. Results. It was established that the highest volume of the pharmaceutical market volume per inhabitant is typical for Italy (410.18 euros) and the lowest for Ukraine (53.58 euros). It has been proven that with an increase in GDP indicators, which are calculated based on purchasing power parity (PPP) per capita, the range of variation of this indicator by groups decreases, and the number of countries with a negative value of the foreign trade balance also decreases. Within groups of countries, there is a different level of dependence on the import of pharmaceutical products. In Ukraine (the first group), imports exceeded the export data of pharmaceutical products by 8.6 times. For other countries in this group (Latvia, Bulgaria, and Slovakia), imports exceeded exports by 1.3, 1.4, and 4.0 times, respectively. The highest values of the volume of foreign trade in pharmaceutical products were characteristic of the countries of the third and second groups. The undisputed leader is Germany (134,541.0 million euros), in second place is Italy (59,533.0 million euros), and in third place is France (58,568.0 million euros). The highest values of health care costs as a percentage of GDP (%) are typical for the countries of the third group and the lowest for the countries of the first group. For all countries, this indicator had a characteristic tendency to increase over time. Growth rates varied both across groups and within groups across countries. According to the indicator of the amount of reimbursement of the cost of drug consumption per person, there was a significant fluctuation of the data by country within the groups. The most extensive range of fluctuations was observed in the third group (284.83 euros). The highest reimbursement amounts are typical for Germany (483.53 euros) and the lowest for Bulgaria (54.25 euros). In most countries, there is a high level (50.0 % and higher) of state participation in the payment of medicine, except for Poland (36.0 %), Lithuania (34.0 %) and Latvia (37.0 %). The lowest values of money consumers spend to pay for medicines (from 13.0 % to 44.0 %) are characteristic of the countries of the third group. Conclusions. The established peculiarities of the functioning of the pharmaceutical supply systems of European countries should not diminish the value of the state's aspirations to harmonize the processes that take place to promote medicinal products to consumers

26 May 2025 in Social Pharmacy in Health Care
Verified
Journal Article
Open access
PDF file
OSO. S. Samborskyi
O. S. Samborskyi
HPH. L. Panfilova
H. L. Panfilova
YBYu. V. Baihush
Yu. V. Baihush
Aim. To develop methodological approaches to the effective implementation of the socially oriented policy in the pharmaceutical market of Ukraine Materials and methods. Historical, analytical-comparative, systemic, graphic, logical, hypothetical-deductive and other methods of theoretical research were used. The study subject was the system of pharmaceutical provision for the population in Ukraine under the conditions of strengthening the humanistic principles of the social development. Results. Based on the results of theoretical research, methodological approaches for the effective implementation of a socially oriented policy in the pharmaceutical market have been developed. The goal has been defined, the tasks have been outlined, and the nature of the functioning of the specified policy in the pharmaceutical market has been described. The main functions (social, stabilizing, stimulating, integrating, controlling, organizational-coordinating, information-correcting) of the implementation of the specified policy have been presented and described. The principles of its implementation in the pharmaceutical market have been outlined with an assessment of the priority of their implementation, which makes it possible to divide them into two groups. The levels (international, national, regional, microeconomic), subjects and objects, terms, conditions and objective obstacles to the effective implementation of the socially oriented policy in the pharmaceutical market of Ukraine have been determined. The directions for implementing the specified policy have been presented in accordance with the levels of pharmaceutical care provided to the population (life-supporting, health-saving, and service level). Based on the results of the systematization and generalization of the research conducted, a strategic dossier has been developed for the process of implementing the socially oriented policy in the pharmaceutical market of Ukraine in accordance with the goals of the National Drug Policy. Conclusions. The implementation of this policy in various directions, levels and terms of its implementation will form an objective basis for transforming the content of relations between the state, society and drug manufacturers on the way to achieving socially fair access of the population to effective medicines in the conditions of the existing resource support of the healthcare system.

13 October 2026 in Social Pharmacy in Health Care
Verified
Journal Article
Open access
PDF file
HPH. L. Panfilova
H. L. Panfilova
OSO. S. Samborskyi
O. S. Samborskyi
LTL. V. Tereshchenko
L. V. Tereshchenko
YBYu. V. Baihush
Yu. V. Baihush
IBIryna Bilyk
Iryna Bilyk
IHI. V. Hadiak
I. V. Hadiak
The development of the “Affordable Medicines” program is a key component of state-building. The introduction of reimbursement for medical products (MPs) in 2023 marked a significant milestone in scaling up the program. Aim. To analyze the state of pharmaceutical provision of patients with MPs in Ukraine under the “Affordable Medicines” program. Materials and methods: Data from regulatory acts and National Health Service of Ukraine (NHSU) dashboards were used. The analysis methods employed were historical, analytical and comparative, system, graphical, mathematical and statistical methods (growth/increase rates, coefficients), etc. Results and discussion. It was found that the number of MPs included in reimbursement lists from August 2023 to September 2026 increased from 23 to 36, while the number of items provided free of charge to patients increased from 2 to 4. These products were supplied by 16 foreign companies. There was a steady increase in the number of packages dispensed and MPs units, the number of patients served, as well as the total reimbursement amounts for MPs. The highest growth rates for these indicators were observed in List No. 3, which comprised 45 trade items. In 2026, the number of prescriptions decreased by 5.02 % compared to the data for List No. 5. The total MPs reimbursement amounts increased 12.9 times from 4,993.35 thousand UAH (August 2023) to 64,330.57 thousand UAH (September 2026). A nearly tenfold increase was noted in the reimbursement amount per prescription (from 652.64 UAH to 1,419.88 UAH, respectively). In turn, the reimbursement amounts and the number of packages dispensed per patient in 2026 (List No. 6) decreased by 3.85 % and 10.09 %, respectively, compared to the data for List No. 5. The largest reimbursement volumes corresponded to cases where patients received MPs without co-payment (83.68 million UAH or 43.39 %), whereas the largest number of patients fell into the category involving co-payment of 200 UAH or more. Conclusions. Despite the war and financial and economic problems, the “Affordable Medicines” program is expanding its support for providing patients with MPs, however, assessing its effectiveness requires a broader set of indicators than those currently presented on the NHSU website.

11 June 2021 in Social Pharmacy in Health Care
Verified
Journal Article
Open access
PDF file
MSM. M. Slobodyanyuk
M. M. Slobodyanyuk
OSO. S. Samborskyi
O. S. Samborskyi
ORO. Yu. Rohulia
O. Yu. Rohulia
YBYu.V. Baygush Baygush
Yu.V. Baygush Baygush
Aim. To substantiate the methodological approach and work out the method for determining economic and marketing components of the cost price, the price and the added value of the drug on the example of Rabeprazole. Materials and methods. Scientific publications, reports of the State Statistics Committee of Ukraine and Centre for Medical Statistics of the MHU, reports and calculations of the cost price of pharmaceutical manufacturers, our own research, as well as methods of systematic, comparative, content-analysis, economic and marketing analysis were used as materials. Results. The stages of work have been summarized, and the algorithm for determining the basic indicators required for manufacturing of drugs has been formed. An extended scheme of calculation of the cost price of products based on the economic approach has been developed; the formation of retail and wholesale price and determination of the wholesale sale value of the drug on the basis of the marketing approach have been studied. The method for determining the basic economic indicators according to the market economic approach, calculation of the added value tax, income and profitability has been worked out on the example of rabeprazole. The distribution of the added value among the subjects of drug promotion and the structure of the added value of the manufacturer have been estimated. Conclusions. The expediency and the necessity of using economic and marketing approaches of the cost management has been substantiated. The cost price and the formation of price for a drug has been calculated, and themethodological approach has been suggested. To assess the total market economic approach as to the determination of the cost price and the price of drug, a graphic scheme of economic and marketing approaches for determining the cost price and the price of drug (progressive retrograde calculation) has been developed. On the example of rabeprazole tablets (0.01 g) the method for determining the cost price, the price, the income and the added value of a drug manufacturer, wholesaler and pharmacy has been studied. The structure of the added value of the drug manufacturer has been characterized.

30 December 2025 in ScienceRise: Pharmaceutical Science
Verified
Journal Article
Open access
PDF file
HPHanna Panfilova
Hanna Panfilova
MMMarta Matushchak
Marta Matushchak
OSOleh Samborskyi
Oleh Samborskyi
Alina VolkovaAlina Volkova
Alina Volkova
LTLiubov Tereshchenko
Liubov Tereshchenko
HTHalyna Tsikhon
Halyna Tsikhon
Regulation of drug availability is one of the most important areas of state policy in the pharmaceutical market. The use of various methods of price regulation allows achieving the desired socio-economic results, but the complexity of the processes taking place in the pharmaceutical market and in the state necessitates the constant revision of existing approaches and measures. The aim: to conduct an analysis of macroeconomic indicators characterizing the state of development of healthcare systems in countries that are reference for the domestic pharmaceutical market. Materials and methods. General theoretical (historical, formal, graphical, hypothetical-deductive, etc.) and applied (organizational-economic, mathematical-statistical, etc.) research methods were used. The subject of the research was the World Bank health indicators, which are integrated with WHO data, and data from the Organization for Economic Cooperation and Development for reference countries (Poland, Slovakia, the Czech Republic, Latvia, Hungary, Romania, Moldova, Bulgaria) and in Ukraine. Results. It was found that for the vast majority of indicators characterizing the state of health care financing, domestic indicators significantly differed from the average values for the group of reference countries. For indicators of domestic health care expenditures (four indicators), domestic data had critically low values (52.12% –% in current healthcare spending, expenditures per capita, including at purchasing power parity of the population – $ 192.81 and $ 570.60, respectively). Only for the indicator of domestic public health care expenditures as a% of general government expenditures, Ukrainian indicators (10.56%) were within the fluctuation range of the corresponding data for the group of reference countries. A comparative analysis of current healthcare expenditures (3 indicators) showed that out of the three indicators, the values of two in Ukraine were close to the minimum values in the group of reference countries. These are current healthcare expenditures per capita, including at purchasing power parity. In Ukraine, the values of these indicators were $369.90 and $1095.06, which were 3.72 and 2.49 times lower than the average values for the group of reference countries. According to the indicators characterizing the participation of private capital and citizens in healthcare expenditures (5 indicators), it was established that per capita private expenditures in Ukraine were $177.10, which was 1.88 times lower than the average for the group of reference countries ($332.58). In terms of private and out-of-pocket expenditures as a% of current healthcare expenditures, domestic data had the highest values compared to reference countries. Thus, private and out-of-pocket expenditures in Ukraine were 1.76 and 1.88 times higher than the average values for reference countries (27.07% and 24.04%, respectively). Domestic out-of-pocket expenditures calculated per capita ($167.54) and at purchasing power parity ($ 495.88) were 44,49% and 17,51% lower than the corresponding average values for the group of reference countries ($301.82 and $ 601.10, respectively). It was found that within the group of reference countries, the drug consumption index varied. This index ranged from $523.0 (Poland) to $883.0 (Bulgaria). The average consumption value in Ukraine for 2021-2023 was ($112.33), which was 5.79 times less than the corresponding data for the group of reference countries. In addition, in the group of reference countries, there are fundamental differences in the structure of population spending on medicines by funding sources (state, private revenues, and health insurance funds). Conclusions. Significant differences in macroeconomic indicators characterizing the state of healthcare financing in the reference countries and in Ukraine have been identified. This necessitates further research on the topic and a review of the group of reference countries used in the domestic pharmaceutical market to regulate the socio-economic accessibility of medicines for the population

26 May 2022 in Social Pharmacy in Health Care
Verified
Journal Article
Open access
PDF file
OSO. S. Samborskyi
O. S. Samborskyi
MSM. M. Slobodyanyuk
M. M. Slobodyanyuk
ORO. Yu. Rohulia
O. Yu. Rohulia
YBYu. V. Baygush
Yu. V. Baygush
Aim. To study and assess the components of the trademark complex, as well as to determine the market power of anti-allergic drugs on the example of Cetirizine. Materials and methods. Scientific publications, reports of the State Statistics Committee of Ukraine and the Center for Medical Statistics of the Ministry of Health of Ukraine, the results of monitoring the retail pharmaceutical market of the “Pharmastandard” system of the “Morion” company, the results of the own research, as well as methods of content and marketing analysis, statistical processing were used as materials. Results. The necessity of further development and deepening of studies of the components of the complex of trademarks (TM) of drugs, changes of market positions of drugs within TM and its highest brand level has been substantiated. It has been recommended to include the notion of “confidence” to the manufacturer and a specific drug to the qualitative consumer characteristics; this notion acts as an indicator of the future strengthening of the drug market positions. On the example of ten drugs of Cetirizine, the assessment of consumer and market indicators of market power of ten drugs based on Cetirizen has been done using a questionnaire survey. A scale of values of the characteristics of the market positions of the TM Cetirizine complex has been developed, and the state of TM and brands at five levels of each has been assessed. The distribution of ten drugs of Cetirizine has been done in the conventional competitive environment using the marketing map. Ten areas of market positions of the TM complex and brands have been identified. The assessment of individual components of TM, which characterize the market power of Cetirizine antiallergic drugs has been performed. Conclusions. Consumer and market indicators of the market power of drugs based on Cetirizine have been characterized. It has been recommended to include the notion of “confidence” to the manufacturer and a specific drug to the consumer characteristics of the TM complex. Based on the questionnaire survey of respondents, single and generalized indicators of ten drugs of Cetirizine have been determined, their levels have been calculated, and a scale of values of the market power characteristics of the TM drug complex has been developed. The state of TM and brands of Cetirizine drugs have been assessed by five levels ranging from absence to a very strong market position. The levels of TM of Cetirizine drugs have been assessed using the scale of values. By using the marketing map the TM distribution of ten drugs of Cetirizine has been done in the competitive market environment, and the areas of market positions have been identified. The components of the TM complex that characterize the market power of drugs based on Cetirizine have been assessed.